B16-huCD20 tumors treated with 177Lu-TRT were subjected to multiplex analysis to study the tumor immune signature.
Ontology highlight
ABSTRACT: B16-huCD20 tumors treated with 177Lu-TRT were subjected to multiplex analysis to study the tumor immune signature.
PROVIDER: PRJNA820864 | ENA |
REPOSITORIES: ENA
ACCESS DATA